Clinical trials: Injector
Osteoarthritis, Knee, Osteoarthritis, Hip
To Assess the Patients' Ability to Self-Administer Fasinumab
The primary objective is to demonstrate that the auto-injector(AI) is suitable to be used to administer fasinumab at home by patients or their caregivers, as measured by collecting 12 weeks of actual-use data on the technical…
- Trial name
- FACT DEVICE (NCT03491904)
- Testing
- Fasinumab AI, Fasinumab PFS
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy Male Subjects
A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects
This is phase 1 study to Compare the Pharmacokinetics, Safety and Immunogenicity of the Auto-injector and Pre-filled syringe of CT-P52 in Healthy Male Subjects.
- Trial name
- NCT07367958
- Testing
- CT-P52
- Where
- South Korea
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- Celltrion
Needle-free Injector
Evaluation by Magnetic Resonance Imaging of Intramuscular Injections Performance in Thigh With 2 Configurations of the Needle-free Injector ZENEO®.
The aim of this study is to establish with measures of clinical parameters by Magnetic Resonance Imaging (MRI) (e.g. crossing of the muscle fascias, length of run, injection depth, volume injected) performance of 2 configurations…
- Trial name
- MRI (NCT05967013)
- Testing
- Injections in thigh of 0.625 mL of physiological serum with ZENEO® injector, on bare skin and through clothing.
- Where
- France
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Crossject
Plaque Psoriasis
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis.
- Trial name
- UNCOVER-A (NCT01777191)
- Testing
- Ixekizumab Auto-Injector, Ixekizumab Prefilled Syringe
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Neuroendocrine Tumors
A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET
This study aims to investigate the treatment preferences of patients with Neuroendocrine Tumors (NETS) and nurses who are involved in the care of individuals with NETs.
- Trial name
- NCT05922579
- Where
- Australia
- Volunteers
- 191 people
- Sponsor
- Ipsen
Rheumatoid Arthritis
An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis
An open-label, single arm study to estimate the rate of failure of the Enbrel® SureClick™ Auto-injector in RA subjects.
- Trial name
- NCT00346294
- Testing
- Etanercept
- Volunteers
- 115 people
- Sponsor
- Amgen
Atopic Disorders, Eczema, Atopic
Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis
To collect data on actual-use to assess technical performance and user injections of dupilumab auto-injection device by patients with atopic dermatitis (AD).
- Trial name
- NCT03050151
- Testing
- Dupilumab, Auto-injector Device, Prefilled syringe
- Where
- 37 sites in United States
- Volunteers
- 176 people
- Sponsor
- Regeneron Pharmaceuticals
Aesthetics
Study to Evaluate Restylane Vital Light Using an Injector Device
The purpose of the study is to evaluate the safety and efficacy of Restylane Vital White administered with an injector device on aged skin in the face, hands and décolletage.
- Trial name
- NCT01412190
- Testing
- Restylane Vital Light, No treatment
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Lupus Erythematosus, Systemic
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus
The purpose of this study is to evaluate the amount of tabalumab in the blood after it is given by two different injection methods - A traditional syringe or a spring loaded syringe for 12 weeks.
- Trial name
- NCT02041091
- Testing
- Tabalumab Auto-Injector, Tabalumab Prefilled Syringe
- Where
- 44 sites in United States, Puerto Rico and 1 more
- Volunteers
- 226 people
- Sponsor
- Eli Lilly and Company
Hypercholesterolaemia
Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
Primary Objective: To collect real-use (usability) data assessing the robustness and user interaction of the new alirocumab auto-injector device (which is referred to as SYDNEY), in unsupervised settings.
- Trial name
- NCT03415178
- Testing
- Alirocumab SAR236553, Current auto-injector device (AI), New auto-injector device (SYDNEY)
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sanofi
Healthy Participants
A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab
A research study to investigate how quickly and to what extent different compositions of the study medicine ziltivekimab are absorbed, transported, and eliminated from the body. Ziltivekimab is not yet approved for market.
- Trial name
- NCT05721989
- Testing
- Ziltivekimab B, Ziltivekimab D, Ziltivekimab C
- Where
- 2 sites in Hungary, Netherlands
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes
Comparison of Safety and Efficacy of QS-M Needle- Free Injector and Insulin Pen in Controlling T2DM Patient's Glucose
In this study, QS-M needle-free injector and needle-insulin pen were used as a drug carrier to control blood glucose in type 2 diabetic patients（T2DM）.The efficacy and safety of QS-M needle-free injector and needle-insulin pen…
- Trial name
- NCT03243903
- Testing
- QS-M insulin-free injector, conventional insulin pen
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Beijing QS Medical Technology Co., Ltd.
Healthy Volunteer
A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants
This study is a multi-center, single-arm, open-label study in healthy participants to assess the pain, tolerability, injection leakage, safety, and usability of a single self-administered subcutaneous (SC) dose of etrolizumab.
- Trial name
- NCT02629744
- Testing
- Etrolizumab, Prefilled Auto-injector (Rotaject)
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Diabetes Mellitus, Type 2
A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools
This study will compare four different semaglutide versions and different injection tools. The study aims to show similar levels of semaglutide in the blood using different versions of semaglutide.
- Trial name
- NCT03598621
- Testing
- Semaglutide, 0.5 mg/mL, Semaglutide, 1.0 mg/mL, Semaglutide, 1.34 mg/mL
- Where
- 2 sites in Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy
Bioavailability Study of Midazolam Administered as a Solution by Conventional Syringe or ZENEO®
Primary objective of this study is to describe the plasma pharmacokinetics of midazolam after single intramuscular injection on bare skin in the thigh by the needle-free injector Zeneo® compared to injection on bare skin in the…
- Trial name
- NCT05026567
- Testing
- 2 ml of DORMICUM® Midazolam Hydrochloride (15 mg/3 mL), ZENEO® Midazolam (10 mg/0.625 mL) on bare skin in thigh, ZENEO® Midazolam (10 mg / 0.625 mL) on bare skin in ventrogluteal area
- Where
- South Africa
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Crossject
Healthy Volunteer
A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers
This open-label, multi-center study will compare the bioavailability of RoActemra/Actemra (tocilizumab) administration by auto-injector versus pre-filled syringe in healthy volunteers.
- Trial name
- NCT01418989
- Testing
- tocilizumab [RoActemra/Actemra] Syringe, tocilizumab [RoActemra/Actemra] auto-injector
- Where
- 2 sites in France
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Asthma
A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug
Mepolizumab (SB-240563) is a humanized monoclonal antibody (Immunoglobulin G1, kappa, mAb) that blocks human interleukin-5 (hIL-5) from binding to the interleukin (IL)-5 receptor complex expressed on the eosinophil cell surface…
- Trial name
- NCT03014674
- Testing
- Lyophilized mepolizumab, Liquid mepolizumab, Prefilled autoinjector
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects
This study will assess the pharmacokinetic (PK) and safety of a single 0.8 mL (40 mg) subcutaneous (SC) dose of M923 administered via an auto-injector (AI) or a prefilled syringe (PFS) in healthy subjects.
- Trial name
- NCT02675023
- Testing
- M923
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 603 people, healthy volunteers welcome
- Sponsor
- Momenta Pharmaceuticals, Inc.
Hypogonadism
Pharmacokinetic Study of Testosterone Enanthate
Relative Bioavailability and Safety comparison of 3 formulations of Testosterone Enanthate.
- Trial name
- NCT01887418
- Testing
- QuickShot™ - 50 mg Treatment B, QuickShot™ - 100 mg Treatment A, Delatestryl 200 mg IM Treatment C
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Antares Pharma Inc.
Computed Tomography
Study to Test the Usability of a New Injector to Administer Contrast Media Into Humans for Diagnostic Purposes
This study investigates if a new medical device, which injects contrast media and flushing solution into humans to increase the visibility of images taken of the human body for diagnostic purposes, is easier to handle, quicker…
- Trial name
- PERCENT (NCT03875469)
- Testing
- Centargo injector (BPI 1000045), Stellant MP injector
- Where
- 2 sites in Australia, Netherlands
- Volunteers
- 425 people
- Sponsor
- Bayer